Title : Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

Pub. Date : 2017 May 9

PMID : 28492898






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens
2 Objective: To compare efficacy of the mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib + docetaxel with docetaxel alone as a second-line therapy for advanced KRAS-mutant NSCLC. AZD 6244 KRAS proto-oncogene, GTPase Homo sapiens